Harvard Bioscience, Inc. (HBIO) Reaches $3.90 52-Week High; Shorts at Chinacache International Holding (CCIH) Raised By 18.01%

January 14, 2018 - By Darrin Black

Chinacache International Holding (NASDAQ:CCIH) had an increase of 18.01% in short interest. CCIH’s SI was 833,600 shares in January as released by FINRA. Its up 18.01% from 706,400 shares previously. With 283,000 avg volume, 3 days are for Chinacache International Holding (NASDAQ:CCIH)’s short sellers to cover CCIH’s short positions. The SI to Chinacache International Holding’s float is 4.25%. The stock decreased 6.57% or $0.19 during the last trading session, reaching $2.7. About 1.11M shares traded. ChinaCache International Holdings Ltd. (NASDAQ:CCIH) has declined 87.12% since January 14, 2017 and is downtrending. It has underperformed by 103.82% the S&P500.

The stock of Harvard Bioscience, Inc. (NASDAQ:HBIO) hit a new 52-week high and has $4.10 target or 5.00% above today’s $3.90 share price. The 7 months bullish chart indicates low risk for the $136.03 million company. The 1-year high was reported on Jan, 14 by Barchart.com. If the $4.10 price target is reached, the company will be worth $6.80M more. The stock increased 0.65% or $0.03 during the last trading session, reaching $3.9. About 206,939 shares traded or 254.90% up from the average. Harvard Bioscience, Inc. (NASDAQ:HBIO) has declined 25.93% since January 14, 2017 and is downtrending. It has underperformed by 42.63% the S&P500.

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company has market cap of $136.03 million. The firm offers cell and animal physiology products, such as syringe pump and peristaltic pump products, as well as a range of instruments and accessories, including surgical products, infusion systems, microdialysis instruments, behavior research systems, and isolated organ and tissue bath systems, as well as in vivo and in vitro electrophysiology recording, stimulation, and analysis systems for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS, TBSI, and HEKA brands. It currently has negative earnings. It also provides products for molecular biology labs comprising pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables under the Denville Scientific and other brands.

Among 2 analysts covering Harvard Bioscience Inc (NASDAQ:HBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Harvard Bioscience Inc had 2 analyst reports since July 28, 2015 according to SRatingsIntel. As per Tuesday, July 28, the company rating was initiated by Benchmark. Singular Research initiated Harvard Bioscience, Inc. (NASDAQ:HBIO) rating on Thursday, November 17. Singular Research has “Buy” rating and $5.50 target.

Investors sentiment decreased to 0.91 in 2017 Q3. Its down 0.18, from 1.09 in 2017Q2. It is negative, as 8 investors sold Harvard Bioscience, Inc. shares while 15 reduced holdings. 7 funds opened positions while 14 raised stakes. 21.49 million shares or 1.39% more from 21.19 million shares in 2017Q2 were reported. Goldman Sachs holds 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 21,884 shares. Meristem Llp has invested 0.02% in Harvard Bioscience, Inc. (NASDAQ:HBIO). Glacier Peak Capital Ltd Co owns 1.33M shares. 16,250 are held by Icm Asset Mgmt Inc Wa. Schwab Charles Invest Mngmt accumulated 19,300 shares. First Light Asset Management Lc has 4.89% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 4.12 million shares. Sei Invs stated it has 735 shares or 0% of all its holdings. Clarivest Asset Limited Co reported 160,500 shares. Geode Cap Ltd Liability Com reported 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO). Moreover, California Employees Retirement Systems has 0% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 139,202 shares. Dimensional Fund Lp, a Texas-based fund reported 1.74M shares. Morgan Stanley owns 25,446 shares. Panagora Asset Mgmt Inc reported 10,265 shares. Acadian Asset Mgmt Ltd Liability Com holds 0.01% in Harvard Bioscience, Inc. (NASDAQ:HBIO) or 709,755 shares. First Manhattan reported 131,000 shares.

Analysts await Harvard Bioscience, Inc. (NASDAQ:HBIO) to report earnings on March, 8. They expect $0.03 EPS, up 200.00% or $0.02 from last year’s $0.01 per share. HBIO’s profit will be $1.05 million for 32.50 P/E if the $0.03 EPS becomes a reality. After $0.01 actual EPS reported by Harvard Bioscience, Inc. for the previous quarter, Wall Street now forecasts 200.00% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News